The earnings call reflected strategic progress with asset sales and pipeline advancements, but also highlighted financial challenges in terms of revenue decline in diagnostics and increased net loss due to restructuring expenses.

Company Guidance

During the second quarter of 2025 conference call, OPKO Health provided several key metrics and strategic updates. The company's revenue for the quarter was $156.8 million, with $101.1 million from diagnostics and $55.7 million from pharmaceuticals. The diagnostics segment reported an operating loss of $18.2 million, a significant improvement from the previous year. The pharmaceutical division saw a slight increase in revenue, with Rayaldee contributing $7.2 million. OPKO is advancing its therapeutic pipeline, with two ModeX programs in Phase I clinical trials and three more expected to enter clinical trials by early 2026. The company highlighted the potential of its GLP-1/glucagon agonist, OPK-88006, for obesity and MASH, and its collaboration with Entera Bio on an oral formulation. Additionally, OPKO's strategic transactions, including the sale of BioReference's oncology assets to Labcorp for $225 million, are expected to streamline operations and improve profitability. The company maintains a $200 million stock repurchase program, with $141.5 million remaining. Overall, OPKO remains focused on maximizing shareholder value through strategic capital deployment and business development initiatives.

BioReference Health Streamlining and Asset Sale

OPKO Health is in the process of selling its oncology and related clinical testing business to Labcorp for $225 million, with $192.5 million payable at closing. This transaction is expected to improve BioReference's financial profile and focus on core clinical testing operations.

4Kscore Test FDA Approval

The FDA granted approval for a supplemental application of the 4Kscore test, allowing it to be performed without digital rectal examination information, enabling broader use by primary care providers.

Growth in 4Kscore Test Volumes

4Kscore test volumes increased by approximately 12% year-over-year, with expectations for further growth following FDA approval.

Advancement in Pharmaceutical Pipeline

OPKO has multiple programs in Phase I clinical trials, including a partnership with Merck on an EBV vaccine and collaboration with Entera Bio on oral formulations of GLP-1/glucagon agonist and GLP-2 candidate.

Rayaldee and Latin American Pharmaceutical Performance

Rayaldee maintained revenue of $7.2 million for both 2025 and 2024 with improved margins, while the Latin American Pharmaceutical division continued to perform well.

Opko Health (OPK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OPK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.08 / -	0.03	―	―	―
Jul 31, 2025	2025 (Q2)	-0.11 / -0.19	-0.01	-1800.00% (-0.18)	―
Apr 30, 2025	2025 (Q1)	-0.07 / -0.10	-0.12	16.67% (+0.02)	―
Feb 27, 2025	2024 (Q4)	-0.09 / 0.01	-0.09	111.11% (+0.10)	―
Nov 07, 2024	2024 (Q3)	-0.09 / 0.03	-0.11	127.27% (+0.14)	―
Aug 07, 2024	2024 (Q2)	-0.10 / -0.01	-0.03	66.67% (+0.02)	―
May 07, 2024	2024 (Q1)	-0.10 / -0.12	-0.02	-500.00% (-0.10)	―
Feb 27, 2024	2023 (Q4)	-0.10 / -0.09	-0.11	18.18% (+0.02)	―
Nov 06, 2023	2023 (Q3)	-0.10 / -0.11	-0.11	0.00% (0.00)	―
Aug 03, 2023	2023 (Q2)	-0.07 / -0.03	-0.14	78.57% (+0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OPK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$1.28	$1.19	-7.03%
Apr 30, 2025	$1.38	$1.35	-2.17%
Feb 27, 2025	$1.63	$1.74	+6.75%
Nov 07, 2024	$1.45	$1.52	+4.83%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Opko Health (OPK) report earnings?

Opko Health (OPK) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Opko Health (OPK) earnings time?

Opko Health (OPK) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OPK EPS forecast?

OPK EPS forecast for the fiscal quarter 2025 (Q3) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing